Completed PHASE2 INTERVENTIONAL NCT00190047

Effects Of DP-b99 On Neurological Function In Subjects With Acute Ischemic Hemispheric Stroke

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Study To Evaluate The Effects Of DP-b99 On Neurologic Function And Disability In Subjects With Acute Ischemic Hemispheric Stroke

Sponsor: D-Pharm Ltd.

Conditions Brain Ischemia Cerebrovascular Disorders Stroke

Interventions DP-b99

Updated 6 times since 2017 Last updated: Nov 22, 2007 Started: Feb 28, 2005 Completion: Oct 31, 2006

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Brain Ischemia and Cerebrovascular Disorders and is currently completed. D-Pharm Ltd. leads this study, which shows 6 recorded versions since 2005 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

6 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Jan 2021 — Jul 2024 [monthly]

Completed PHASE2
Jun 2018 — Jan 2021 [monthly]

Completed PHASE2

▶ Show 1 earlier version

Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Feb 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

D-Pharm Ltd.

Data source: D-Pharm Ltd.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Bad Neustadt / Saale, Germany , Berlin, Germany , Cologne, Germany , Essen, Germany , Freiburg im Breisgau, Germany , Haifa, Israel , Holon, Israel , Jerusalem, Israel , Leipzig, Germany , Magdeburg, Germany and 11 more locations